Ontology highlight
ABSTRACT:
SUBMITTER: Forde PM
PROVIDER: S-EPMC3689308 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature
Forde Patrick M PM Antonarakis Emmanuel S ES
The International journal of targeted therapies in cancer 20120901 3
Until recently, treatment options for castration-resistant prostate cancer (CRPC) were limited to only the chemotherapeutic agent docetaxel which demonstrated a survival advantage over palliative chemotherapy. Abiraterone acetate (AA) is an orally available, potent irreversible inhibitor of the adrenal microsomal enzyme cytochrome P450-17 (CYP17). In a large phase III study of AA in docetaxel-pretreated patients, AA demonstrated excellent tolerance and a 4-month survival advantage over placebo, ...[more]